MK-2048
MK-2048
MK-2048 (pronunciation: em-kay-two-zero-four-eight) is a second-generation integrase inhibitor used in the treatment of HIV infections. It is a derivative of raltegravir, the first approved integrase inhibitor, and has shown to be effective against HIV strains resistant to raltegravir.
Etymology
The name "MK-2048" is a product code assigned by the pharmaceutical company Merck & Co., with "MK" standing for Merck and "2048" being a sequential number in their drug development program.
Mechanism of Action
MK-2048 inhibits the integrase enzyme, which is essential for the replication of HIV. By blocking this enzyme, MK-2048 prevents the virus from integrating its genetic material into the host cell, thereby stopping the replication process.
Related Terms
- Integrase Inhibitors: A class of antiretroviral drugs that block the integrase enzyme, preventing HIV from integrating its genetic material into the host cell.
- Raltegravir: The first approved integrase inhibitor, from which MK-2048 is derived.
- HIV: Human Immunodeficiency Virus, the virus that causes AIDS. MK-2048 is used in the treatment of HIV infections.
- Merck & Co.: The pharmaceutical company that developed MK-2048.
External links
- Medical encyclopedia article on MK-2048
- Wikipedia's article - MK-2048
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski